A third randomized controlled trial was designed to evaluate the effect of a lower RYR dose (one capsule a day) on total and LDL cholesterol in individuals with moderate hypercholesterolemia. A total of 40 patients were randomized to receive once-daily RYR or a placebo for eight weeks. Patients’ blood samples were collected every four weeks, and four weeks after trial completion. In the RYR group, there was a 20% reduction in plasma LDL-C after four weeks, which was maintained at eight weeks; LDL-C levels returned to baseline after the four-week washout period. Similarly, there was a 12% reduction in total cholesterol by four weeks of treatment. There were no changes in total cholesterol or LDL-C in the placebo group.
References:
Liu SF, Wang YR, Shen YC, et al. A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation. J Food Drug Anal. 2016;6(110):393-400. doi:10.1016/j.jfda.2017.04.006.
